ClearPoint Neuro announces the full market launch of

SOLANA BEACH, Calif., June 1, 2024 (GLOBE NEWSWIRE) — ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell and gene therapy enabler providing precise navigation to the of the brain and spine, today announces the full market launch of its SmartFrame OR platform and its ClearPoint Prism neuro-laser therapy system at the show 2024 Biennial Meeting of the American Society of Stereotactic and Functional Neurosurgery from Saturday June 1st^st – Tuesday June 4^th in Nashville.

“Deep brain stimulation (DBS) has been shown to be a safe and effective strategy to manage patients with medically incurable Parkinson’s disease, essential tremor, and dystonia.¹“, said Dr. Kim Burchiel, professor of neurological surgery at Oregon Health & Science University. “During its more than 30-year history in the United States, this highly effective therapy has been primarily performed in neurosurgical centers highly specialized, which, due to their relative rarity, only made it possible to treat approximately 5% of eligible patients.¹ The development of the SmartFrame OR is expected to be an important step towards achieving the Triple Aim of achieving excellent results in an accessible and appropriate clinical setting, with broad patient acceptance, as it is expected to enable DBS procedures to be performed in a much broader framework. range of hospitals, by a larger contingent of well-trained neurosurgeons.

“ClearPoint Neuro’s new SmartFrame OR solution supports stereotaxic precision in an efficient, intuitive and reliable platform,” said Dr. Andrew Conner, assistant professor of neurosurgery at the University of Oklahoma. “It has completely changed my DBS practice for the better since its release. »

“This is a truly exciting milestone for ClearPoint that has been years in the making,” commented Joe Burnett, President and CEO of ClearPoint Neuro. “We set out to prove that we are one of the most innovative and focused companies in the field of neurosurgery. We now enter the first stereotactic neurosurgery conference capable of demonstrating new laser therapy, new operating room navigation, new brain modeling software, new access products and new preclinical testing services and medication administration clinics. This is a significant innovation that will ultimately benefit our surgical customers and, more importantly, many new patients around the world.

At the ASSFN, the SmartFrame OR and ClearPoint Prism neurolaser therapy system will be presented to:

About ClearPoint Neuro

ClearPoint Neuro is a device, cell and gene therapy company providing precise navigation to the brain and spine. The company uniquely provides both established clinical products as well as preclinical development services for controlled drug and device delivery. The company’s flagship product, the ClearPoint Neuro navigation system, has received FDA clearance and is CE marked. ClearPoint Neuro collaborates with healthcare and research centers in North America, Europe, Asia and South America. The company also partners with the most innovative pharmaceutical/biotechnology companies, academic centers, and contract research organizations, providing solutions for the direct delivery of therapeutics to the CNS in preclinical and clinical studies. clinical trials around the world. To date, thousands of procedures have been performed and supported by the company’s team of field clinical specialists, who provide support and services to our customers and partners around the world. For more information, please visit www.clearpointneuro.com.

Forward-looking statements

This press release contains forward-looking statements within the context of the federal securities laws, which may include the Company’s expectations regarding future performance, market and revenue of its products and services. These forward-looking statements are based on management’s current expectations and are subject to inherent risks of the business, which may cause the Company’s actual results to differ materially from those expressed or implied in the forward-looking statements. Particular uncertainties and risks include those related to: global and political instability, supply chain disruptions, labor shortages and macroeconomic and inflationary conditions; future revenues from sales of the Company’s products and services; the Company’s ability to commercialize and achieve broader market acceptance for new products and services offered by the Company; the ability of our biologics and drug delivery partners to achieve commercial success, including their use of the Company’s products and services in their provision of therapies; the Company’s expectations, projections and estimates regarding expenses, future revenues, capital requirements and the availability and need for additional financing; the Company’s ability to obtain additional financing to support its research and development programs; the Company’s ability to manage the growth of its business; the Company’s ability to attract and retain its key employees; and risks inherent in the research, development and regulatory approval of new products. More detailed information about these and other factors that could affect the Company’s actual results is described in the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the year ended December 31. 2023, and in the company’s quarterly report on form. 10-Q for the three months ended March 31, 2024, both filed with the Securities and Exchange Commission. The Company undertakes no obligation to update these forward-looking statements.

¹ Data archived at ClearPoint Neuro

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/ef08f4c6-fb7a-4470-b834-6589a0a3adfd

A video accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/dc00d91c-8a9a-410b-a41a-c435136a10b5.